Abstract: A vaccine composition for intranasal administration includes a Bordetella pertussis antigen, and an effective adjuvant amount of a high molecular weight glucose polymer. The high molecular weight glucose polymer may be a beta-glucan. The Bordetella pertussis antigen may be an extracellular toxin, an adhesion protein, an outer membrane protein, a receptor protein, a fragment thereof, or a mixture thereof.
Abstract: A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Podoviridae bacteriophage (Esc-COP-30) having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Podoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Podoviridae bacteriophage.
Type:
Grant
Filed:
June 4, 2020
Date of Patent:
July 18, 2023
Assignee:
iNtRON Biotechnology, Inc.
Inventors:
Seong Jun Yoon, Jee Soo Son, In Hwang Kim, Hyoung Rok Paik, Hyun Joo Im, Hyun Jin Yu, Beom Seok Kim, Geun Woo Lee, Soo Youn Jun, Sang Hyeon Kang
Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting pigs against an infection with Streptococcus suis of serotype 2 and against an infection with Streptococcus suis of serotype 14.
Abstract: The present invention relates to methods for inducing an immune response, in particular methods for adjuvanting the immune response to an antigen comprising the separate administration of a saponin and a TLR4 agonist.
Type:
Grant
Filed:
November 27, 2020
Date of Patent:
June 20, 2023
Assignee:
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors:
Margherita Coccia, Arnauld Michel Didierlaurent
Abstract: The present invention relates to the field of native outer membrane vesicles (nOMVs), particularly nOMVs having increased levels of lipoproteins on their surface and use of same in immunogenic compositions.
Abstract: Provided are therapeutic compositions containing combinations of bacteria, for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for use thereof.
Type:
Grant
Filed:
January 4, 2021
Date of Patent:
June 6, 2023
Assignee:
Seres Therapeutics, Inc
Inventors:
Matthew R. Henn, David N. Cook, Toshiro K. Ohsumi, Mary-Jane Lombardo McKenzie, Kevin D. Litcofsky, Han Zhang, John Grant Aunins, David Arthur Berry
Abstract: Provided are attenuated strains of M. tuberculosis and M. bovis BCG which are double auxotrophic mutants with genes knocked out in the biosynthetic pathways for arginine and methionine, and compositions and methods of use thereof.
Type:
Grant
Filed:
August 15, 2019
Date of Patent:
June 6, 2023
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE
Inventors:
William R. Jacobs, Jr., Sangeeta Tiwari
Abstract: Disclosed herein are compositions having standardized potencies for use in the treatment of warts. Methods of treating a common wart comprising administering one or more intralesional injections of compositions having standardized potencies to a patient in need thereof are also disclosed. Further disclosed are methods of treating a non-common wart administering one or more intralesional injections of compositions having standardized potencies to a patient in need thereof.
Abstract: Disclosed are a novel recombinant transition vector for increasing expression of a foreign protein in a native form without fusion partners, and a method for mass production of a foreign target protein using the same. The recombinant transition vector according to the present disclosure may allow a large amount of a foreign target protein with a high therapeutic and prophylactic value to be expressed in an insect cell. In particular, the vector may increase the expression of the foreign target protein in an own form thereof, not fused with other fusion partners. Therefore, the use of the recombinant transition vector may produce useful proteins such as antigens in insect cells at low cost and high efficiency.
Type:
Grant
Filed:
March 7, 2018
Date of Patent:
May 23, 2023
Assignees:
OPTIPHARM CO., LTD, CHUNGBUK NATIONAL UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
Inventors:
Soo Dong Woo, Ji Hoon Lee, Won Seok Gwak, Ji In Ma, Beom Ku Han, Hyun Il Kim, Charl Se Park, Jae Bang Choi
Abstract: Provided herein are compositions and methods comprising microbiome biomarkers of responsiveness/resistance to immunotherapy (e.g., anti-PD1/PD-L1 therapy), and diagnostic, prognostic and therapeutic uses thereof. In particular, the amount, identity, presence, and/or ratio of microflora in the microbiome of a subject is used to determine the responsiveness/resistance of the subject to immunotherapy, and/or the microbiome of a subject is manipulated to enhance the responsiveness of the subject to various immunotherapies and co-therapies.
Type:
Grant
Filed:
June 5, 2018
Date of Patent:
May 2, 2023
Assignee:
The University of Chicago
Inventors:
Thomas F. Gajewski, Jason Luke, Riyue Bao, Vyara Matson, Jessica Fessler
Abstract: A strain of Lactobacillus crispatus KBL693 and the use thereof are disclosed. The strain of Lactobacillus crispatus KBL693 (Accession No. KCTC 13519BP) attenuates allergic reactions of cells, significantly improves symptoms of atopic dermatitis, and exhibits anti-inflammatory and anti-fungal effects. Thus, the single strain alone can achieve all the purposes of alleviating atopic dermatitis and other allergic diseases and improving inflammatory diseases and autoimmune diseases, thereby finding advantageous applications as a probiotic substance. In addition, the strain, based on the anti-fungal activity thereof, can be advantageously utilized in a skin external preparation against various skin diseases caused by fungi, and in a cosmetic composition and a functional patch for alleviating sensitive skin.
Type:
Grant
Filed:
September 23, 2021
Date of Patent:
April 25, 2023
Assignee:
KoBioLabs, Inc.
Inventors:
Woo Ri Ko, June Chul Lee, Tae-Wook Nam, Gwang Pyo Ko, Hyun Ju You, So Yon Yoon, Seok Cheon Song
Abstract: This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.
Type:
Grant
Filed:
December 16, 2021
Date of Patent:
April 18, 2023
Assignee:
Research Institute of Nationwide Children's Hospital
Abstract: Provided is a composition comprising an isolated Lactobacillus paracasei D3.5 strain or cellular components thereof. In some embodiments, the composition is provided in a pharmaceutically acceptable carrier, which may be a food product, tablet or capsule suitable for enteral administration, etc. Also provided is a composition comprising lipoteichoic acid isolated from Lactobacillus paracasei D3.5 strain, which may be provided in a pharmaceutically acceptable carrier.
Abstract: Some embodiments described herein relate to cells which have been genetically engineered to release a polypeptide when a population of the cells reaches a desired density. In some embodiments, the released polypeptide may be a therapeutic polypeptide. In some embodiments, the therapeutic polypeptide kills tumor cells or which inhibits the growth of tumor cells.
Type:
Grant
Filed:
November 11, 2021
Date of Patent:
March 28, 2023
Assignees:
The Regents of the University of California, Massachusetts Institute of Technology
Inventors:
Jeff Hasty, Lev Tsimring, Muhammad Omar Din, Arthur Prindle, Sangeeta Bhatia, Tal Danino
Abstract: The invention relates to a method for the diagnosis and/or risk stratification of invasive fungal infections (IFI)/invasive fungal diseases (IFD) and in particular associated with sepsis or septic shock, wherein a determination of the marker proadrenomedullin (proADM) or a partial peptide or fragment thereof, in particular midregional proadrenomedullin (MR-proADM), or contained in a marker combination (panel, cluster), is carried out from a patient to be examined. Furthermore, the invention relates to a diagnostic assay and a kit for carrying out the method.
Type:
Grant
Filed:
August 6, 2018
Date of Patent:
February 28, 2023
Assignee:
B.R.A.H.M.S GMBH
Inventors:
Thorsten Brenner, Markus Alexander Weigand, Florian Uhle, Darius Cameron Wilson
Abstract: The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioactive agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject. The presently disclosed subject matter further relates to a method of preparing the composition.
Type:
Grant
Filed:
April 15, 2020
Date of Patent:
February 14, 2023
Assignee:
US Biologic, Inc.
Inventors:
Douglas Steven Zatechka, Mason Kauffman, Chris Przybyszewski
Abstract: In certain embodiments, the present invention provides a poultry vaccine comprising an antigenic protein comprising a PlcC protein unit that is operably linked to a peptide linker that is operably linked to a NetB protein unit, where the vaccine is effective in stimulating a protective cellular and/or humoral immune response to C. perfringens. Methods are also provided for making the vaccine and for vaccinating poultry by administering such a vaccine.
Type:
Grant
Filed:
September 14, 2021
Date of Patent:
January 31, 2023
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
Inventors:
Kenneth Roland, Andrew Diamos, Hugh Mason
Abstract: Provided are SpdE polypeptides and variants and nucleic acids encoding the SpdE polypeptides and variants. Also provided are vectors including one or more nucleic acids encoding a SpdE polypeptide or variant and cells including a nucleic acid encoding the SpdE polypeptide or variant, as well as cells expressing a SpdE polypeptide or variant and compositions including such cells and a pharmaceutically acceptable carrier. Finally, methods of detecting presence and/or amount of one or more amino acids in a sample are provided. The methods include contacting the sample with a SpdE protein, measuring diguanylate cyclase activity of the SpdE protein; and comparing the diguanylate cyclase activity of the SpdE protein to a control. The methods can utilize isolated SpdE protein or a cell expressing a SpdE protein.
Abstract: Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as Bacillus Calmette-Guerin (BCG).